What to Expect From Incyte’s Next Quarterly Earnings Report

With a market cap of $23 billion, Incyte Corporation (INCY) is a Delaware–based biopharmaceutical company focused on discovering, developing, and commercializing targeted therapies, primarily in oncology and inflammatory diseases. The company specializes in small-molecule drugs that modulate specific biological pathways, particularly those involved in cancer and immune system disorders.

The company is set to unveil its fiscal Q3 2026 results on Thursday, Oct. 29, before the market opens. Ahead of this event, analysts expect INCY to report a loss of $3.87 per share, down 290.6% from a profit of $2.03 per share in the year-ago quarter. It has surpassed Wall Street's bottom-line estimates in three of the past four quarters while missing on another occasion.